Tiziana Life Sciences ( (TLSA) ) just unveiled an update.
On March 17, 2025, Tiziana Life Sciences announced that its CEO, Ivor Elrifi, will present at the 37th Annual ROTH Conference, held from March 16-18, 2025, in Dana Point, California. The presentation will include a fireside chat and 1×1 investor meetings, highlighting the company’s lead candidate, intranasal foralumab, which has shown promising results in treating non-active secondary progressive multiple sclerosis. This event is a significant opportunity for Tiziana to showcase its innovative therapies to a broad audience of investors and industry leaders, potentially enhancing its market positioning and stakeholder engagement.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company is particularly noted for its intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which is currently in clinical development to treat neuroinflammatory and neurodegenerative diseases.
YTD Price Performance: 130.88%
Average Trading Volume: 1,019,402
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $173.7M
See more insights into TLSA stock on TipRanks’ Stock Analysis page.